/stocks — the workspaceLOADING
Entrada Therapeutics, Inc. (TRDA) is a pharmaceutical preparations company. Piotroski F-Score 4/8. 9 insider Form 4 filings in the last 90 days. Next earnings projected around 2026-08-05 from TRDA's year-over-year reporting pattern (not yet company-confirmed). Fundamentals from SEC filings; prices are end-of-day.
EOD daily bars · delayed, not real-time · data: DatabentoCharting by TradingView Lightweight Charts™
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
FY ending 2025-12-31 vs 2024-12-31. original 1968 formula; calibrated on manufacturers, read financials/REITs with care
A plain-English read on TRDA plus an auto-SWOT — built from TRDA's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate TRDA using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
| Zeiher Bernhardt GDirector | BUY | $29K | view → |
| Dowden Nathan JPresident & COO | SELL | $230K | view → |
| Sethuraman NatarajanPresident, Research & Develop. | SELL | $399K | view → |
| WENTWORTH KORY JAMESChief Financial Officer | SELL | $32K | view → |
| WENTWORTH KORY JAMESChief Financial Officer | SELL | $214K | view → |
| Dowden Nathan JPresident & COO | SELL | $196K | view → |
| WENTWORTH KORY JAMESChief Financial Officer | SELL | $98K | view → |
Projected from TRDA's own SEC 8-K filing history — the year-over-year reporting pattern (~50% land the exact day, ~90% within a week). No analyst estimates, no scraped calendars, nothing invented. It upgrades to a confirmed date + time the moment TRDA files its announcement.
TRDA has sold off after 6 of its last 8 earnings reports.
Large earnings reactions have been common.
TRDA has traded lower after most recent earnings releases.
The average is inflated by its most volatile prints (+2.7% and -57.3%).
A more typical earnings reaction has been approximately ±1.7%.
Realized close-to-close history only — no options-implied move, no analyst estimates.
| Reported | Close-to-close |
|---|---|
| 2026-05-07 | -57.3% |
| 2026-02-26 | -0.4% |
| 2026-01-08 | -6.8% |
| 2025-11-06 | -0.4% |
| 2025-08-06 | -9.1% |
| 2025-05-08 | +2.7% |
| 2025-02-27 |
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
| -0.7% |
| 2025-01-15 | +0.4% |